Cargando…

C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19

PURPOSE: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory coronavirus 2 (SARS-CoV-2) has spread around the world. Differentiation between pure viral COVID-19 pneumonia and secondary infection can be challenging. In patients with elevated C-reactive protein (CRP) on admission ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Pink, Isabell, Raupach, David, Fuge, Jan, Vonberg, Ralf-Peter, Hoeper, Marius M., Welte, Tobias, Rademacher, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140571/
https://www.ncbi.nlm.nih.gov/pubmed/34021897
http://dx.doi.org/10.1007/s15010-021-01615-8
_version_ 1783696213835513856
author Pink, Isabell
Raupach, David
Fuge, Jan
Vonberg, Ralf-Peter
Hoeper, Marius M.
Welte, Tobias
Rademacher, Jessica
author_facet Pink, Isabell
Raupach, David
Fuge, Jan
Vonberg, Ralf-Peter
Hoeper, Marius M.
Welte, Tobias
Rademacher, Jessica
author_sort Pink, Isabell
collection PubMed
description PURPOSE: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory coronavirus 2 (SARS-CoV-2) has spread around the world. Differentiation between pure viral COVID-19 pneumonia and secondary infection can be challenging. In patients with elevated C-reactive protein (CRP) on admission physicians often decide to prescribe antibiotic therapy. However, overuse of anti-infective therapy in the pandemic should be avoided to prevent increasing antimicrobial resistance. Procalcitonin (PCT) and CRP have proven useful in other lower respiratory tract infections and might help to differentiate between pure viral or secondary infection. METHODS: We performed a retrospective study of patients admitted with COVID-19 between 6th March and 30th October 2020. Patient background, clinical course, laboratory findings with focus on PCT and CRP levels and microbiology results were evaluated. Patients with and without secondary bacterial infection in relation to PCT and CRP were compared. Using receiver operating characteristic (ROC) analysis, the best discriminating cut-off value of PCT and CRP with the corresponding sensitivity and specificity was calculated. RESULTS: Out of 99 inpatients (52 ICU, 47 Non-ICU) with COVID-19, 32 (32%) presented with secondary bacterial infection during hospitalization. Patients with secondary bacterial infection had higher PCT (0.4 versus 0.1 ng/mL; p = 0.016) and CRP (131 versus 73 mg/L; p = 0.001) levels at admission and during the hospital stay (2.9 versus 0.1 ng/mL; p < 0.001 resp. 293 versus 94 mg/L; p < 0.001). The majority of patients on general ward had no secondary bacterial infection (93%). More than half of patients admitted to the ICU developed secondary bacterial infection (56%). ROC analysis of highest PCT resp. CRP and secondary infection yielded AUCs of 0.88 (p < 0.001) resp. 0.86 (p < 0.001) for the entire cohort. With a PCT cut-off value at 0.55 ng/mL, the sensitivity was 91% with a specificity of 81%; a CRP cut-off value at 172 mg/L yielded a sensitivity of 81% with a specificity of 76%. CONCLUSION: PCT and CRP measurement on admission and during the course of the disease in patients with COVID-19 may be helpful in identifying secondary bacterial infections and guiding the use of antibiotic therapy.
format Online
Article
Text
id pubmed-8140571
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-81405712021-05-24 C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19 Pink, Isabell Raupach, David Fuge, Jan Vonberg, Ralf-Peter Hoeper, Marius M. Welte, Tobias Rademacher, Jessica Infection Original Paper PURPOSE: Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory coronavirus 2 (SARS-CoV-2) has spread around the world. Differentiation between pure viral COVID-19 pneumonia and secondary infection can be challenging. In patients with elevated C-reactive protein (CRP) on admission physicians often decide to prescribe antibiotic therapy. However, overuse of anti-infective therapy in the pandemic should be avoided to prevent increasing antimicrobial resistance. Procalcitonin (PCT) and CRP have proven useful in other lower respiratory tract infections and might help to differentiate between pure viral or secondary infection. METHODS: We performed a retrospective study of patients admitted with COVID-19 between 6th March and 30th October 2020. Patient background, clinical course, laboratory findings with focus on PCT and CRP levels and microbiology results were evaluated. Patients with and without secondary bacterial infection in relation to PCT and CRP were compared. Using receiver operating characteristic (ROC) analysis, the best discriminating cut-off value of PCT and CRP with the corresponding sensitivity and specificity was calculated. RESULTS: Out of 99 inpatients (52 ICU, 47 Non-ICU) with COVID-19, 32 (32%) presented with secondary bacterial infection during hospitalization. Patients with secondary bacterial infection had higher PCT (0.4 versus 0.1 ng/mL; p = 0.016) and CRP (131 versus 73 mg/L; p = 0.001) levels at admission and during the hospital stay (2.9 versus 0.1 ng/mL; p < 0.001 resp. 293 versus 94 mg/L; p < 0.001). The majority of patients on general ward had no secondary bacterial infection (93%). More than half of patients admitted to the ICU developed secondary bacterial infection (56%). ROC analysis of highest PCT resp. CRP and secondary infection yielded AUCs of 0.88 (p < 0.001) resp. 0.86 (p < 0.001) for the entire cohort. With a PCT cut-off value at 0.55 ng/mL, the sensitivity was 91% with a specificity of 81%; a CRP cut-off value at 172 mg/L yielded a sensitivity of 81% with a specificity of 76%. CONCLUSION: PCT and CRP measurement on admission and during the course of the disease in patients with COVID-19 may be helpful in identifying secondary bacterial infections and guiding the use of antibiotic therapy. Springer Berlin Heidelberg 2021-05-22 2021 /pmc/articles/PMC8140571/ /pubmed/34021897 http://dx.doi.org/10.1007/s15010-021-01615-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Paper
Pink, Isabell
Raupach, David
Fuge, Jan
Vonberg, Ralf-Peter
Hoeper, Marius M.
Welte, Tobias
Rademacher, Jessica
C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19
title C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19
title_full C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19
title_fullStr C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19
title_full_unstemmed C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19
title_short C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19
title_sort c-reactive protein and procalcitonin for antimicrobial stewardship in covid-19
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140571/
https://www.ncbi.nlm.nih.gov/pubmed/34021897
http://dx.doi.org/10.1007/s15010-021-01615-8
work_keys_str_mv AT pinkisabell creactiveproteinandprocalcitoninforantimicrobialstewardshipincovid19
AT raupachdavid creactiveproteinandprocalcitoninforantimicrobialstewardshipincovid19
AT fugejan creactiveproteinandprocalcitoninforantimicrobialstewardshipincovid19
AT vonbergralfpeter creactiveproteinandprocalcitoninforantimicrobialstewardshipincovid19
AT hoepermariusm creactiveproteinandprocalcitoninforantimicrobialstewardshipincovid19
AT weltetobias creactiveproteinandprocalcitoninforantimicrobialstewardshipincovid19
AT rademacherjessica creactiveproteinandprocalcitoninforantimicrobialstewardshipincovid19